Business Description
Kymera Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US5015751044
Share Class Description:
KYMR: Ordinary SharesDescription
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.43 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.59 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 5.81 | |||||
| Beneish M-Score | 0.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.8 | |||||
| 3-Year EBITDA Growth Rate | 0.9 | |||||
| 3-Year EPS without NRI Growth Rate | 7.2 | |||||
| 3-Year Book Growth Rate | 3.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | -0.63 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.55 | |||||
| 9-Day RSI | 36.01 | |||||
| 14-Day RSI | 37.78 | |||||
| 6-1 Month Momentum % | 248.94 | |||||
| 12-1 Month Momentum % | 19.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.73 | |||||
| Quick Ratio | 4.73 | |||||
| Cash Ratio | 4.37 | |||||
| Days Sales Outstanding | 69.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.7 | |||||
| Shareholder Yield % | -2.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -210.62 | |||||
| Net Margin % | -186.99 | |||||
| FCF Margin % | -174.71 | |||||
| ROE % | -33.74 | |||||
| ROA % | -25.1 | |||||
| ROIC % | -74.49 | |||||
| ROC (Joel Greenblatt) % | -197.46 | |||||
| ROCE % | -28.33 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 25.52 | |||||
| PB Ratio | 4.69 | |||||
| Price-to-Tangible-Book | 4.69 | |||||
| EV-to-EBIT | -12.68 | |||||
| EV-to-Forward-EBIT | -8.48 | |||||
| EV-to-EBITDA | -13 | |||||
| EV-to-Forward-EBITDA | -8.89 | |||||
| EV-to-Revenue | 23.69 | |||||
| EV-to-Forward-Revenue | 33.25 | |||||
| EV-to-FCF | -13.56 | |||||
| Price-to-Net-Current-Asset-Value | 8.25 | |||||
| Price-to-Net-Cash | 9.56 | |||||
| Earnings Yield (Greenblatt) % | -7.89 | |||||
| FCF Yield % | -6.74 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers